Add listing
    0
    Add listing

    Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome.

    Indicaton

    Insomnia in ASD

    Therapeutic indications
    Type of product
    Table
    • Phase
      Marketed
    • Available in
      EMA Markets

    You may also be interested in